Stifel Maintains Hold on Health Catalyst, Lowers Price Target to $2
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Stifel analyst David Grossman maintains Health Catalyst (NASDAQ:HCAT) with a Hold and lowers the price target from $3.75 to $2.
Stifel analyst David Grossman maintains Health Catalyst (NASDAQ:HCAT) with a Hold and lowers the price target from $3.75 to $2.